Genetic Associations with Hyperuricemia
Multiple genetic variants are strongly associated with hyperuricemia and gout, with ABCG2, SLC22A12 (URAT1), and SLC2A9 being the most clinically significant genes affecting uric acid transport, while UMOD, MUC1, REN, and HNF1B mutations cause rare monogenic forms of hyperuricemia-associated kidney disease.
Major Genetic Variants Associated with Hyperuricemia and Gout
Urate Transporter Genes (Most Common)
ABCG2 (ATP-Binding Cassette Subfamily G Member 2)
- Encodes a urate exporter in kidneys and intestinal tract
- Dysfunctional variants create the strongest individual and population risk for hyperuricemia progression 1, 2, 3
- Population-attributable fraction (PAF) is approximately 30% for progression of hyperuricemia in Japanese populations—higher than environmental factors like obesity, heavy drinking, or aging 3
- Pathogenic variants include p.I63YfsTer54 (rs565722112) and p.G74D (rs199976573), which are functionally null with deficient plasma membrane localization 2
- These variants affect both males and females and are strong risk factors for severe familial gout 2
SLC22A12 (URAT1 - Urate Reabsorption Transporter)
- Mediates uric acid reabsorption in proximal tubules
- Variants affect renal uric acid underexcretion subtype 4, 5
SLC2A9 (GLUT9 - Glucose Transporter 9)
- Functions as urate transporter
- Variants consistently associated with serum urate levels across populations 1, 5
Monogenic Causes of Hyperuricemia (Rare but Clinically Important)
UMOD (Uromodulin) - ADTKD-UMOD
- Causes autosomal dominant tubulointerstitial kidney disease with hyperuricemia 6
- Characterized by inappropriately decreased fractional urate excretion (<5%), causing hyperuricemia and early-onset gout 6
- Gout can begin in teenage years, especially in males 6
- Hyperuricemia can begin in childhood before significant kidney symptoms 6
- Low urinary excretion of uromodulin is a laboratory marker 6
- Mutations in exons 3 and 4 account for 93% of reported mutations 6
MUC1 (Mucin-1) - ADTKD-MUC1
- Causes tubulointerstitial kidney disease without characteristic hyperuricemia pattern 6
- Requires specialized testing for single base insertion 7
REN (Renin) - ADTKD-REN
- Associated with hyperuricemia, hyperkalemia, and low urinary uromodulin excretion 6
- Presents frequently in childhood with mild hypotension and anemia 6
HNF1B (Hepatocyte Nuclear Factor 1β) - ADTKD-HNF1B
- Associated with MODY5 diabetes, renal cysts, and electrolyte abnormalities 6
- Can present with hypomagnesemia and hypokalemia 6
Pharmacogenetic Variants
HLA-B*5801
- Not directly associated with hyperuricemia but critically important for treatment safety 8
- PCR-based HLA-B*5801 screening should be performed before initiating allopurinol in high-risk populations: Koreans with stage 3 or worse CKD, and all individuals of Han Chinese and Thai descent 8
- These populations have elevated allele frequency and very high hazard ratio for severe allopurinol hypersensitivity reaction 8
Hyperuricemia Subtypes with Distinct Genetic Profiles
Recent research identifies four hyperuricemia subtypes based on renal uric acid handling, each with unique genetic patterns 4:
- Renal Overload (ROL) - 8.8%: Associated with older age at onset, lower serum urate, tophi, diabetes; high polygenic risk score (OR=9.63)
- Renal Underexcretion (RUE) - 60.9%: Associated with lower BMI, non-diabetes; polygenic risk score OR=2.18
- Combined - 23.1%: Associated with younger age at onset, higher BMI, serum urate, eGFR, smoking; polygenic risk score OR=6.32
- Renal Normal - 7.2%: Associated with older age at onset, lower serum urate and eGFR
Thirteen SNPs were associated with gout, with 6 shared loci and subtype-dependent risk loci patterns 4.
Clinical Implications
When to Consider Genetic Testing:
- Family history of young-onset gout (onset under age 25) 9
- Renal calculi with hyperuricemia 9
- Progressive kidney disease with bland urinary sediment, minimal proteinuria, and hyperuricemia 6
- Severe familial gouty phenotypes 2
- Related kidney donor candidates when recipient has hyperuricemia-associated kidney disease 7
Genetic testing should follow sequential approach: Test affected individual first, then cascade testing for at-risk family members 7, 6.
The genetic architecture of hyperuricemia involves both common variants with modest effects (like ABCG2 polymorphisms affecting 30% of population risk) and rare monogenic causes with high penetrance (like UMOD mutations causing inevitable disease) 1, 5. Understanding these genetic contributions enables personalized risk assessment and treatment strategies 3, 10.